Advertisement

The Impact of Breast Density Notification Laws on Supplemental Breast Imaging and Breast Biopsy

  • Loren Saulsberry
  • Lydia E. Pace
  • Nancy L. KeatingEmail author
Original Research

Abstract

Background

Dense breast tissue increases breast cancer risk and lowers mammography sensitivity, but the value of supplemental imaging for dense breasts remains uncertain. Since 2009, 37 states and Washington DC have passed legislation requiring patient notification about breast density.

Objective

Examine the effects of state breast density notification laws on use of supplemental breast imaging and breast biopsies.

Design

Difference-in-differences analysis of supplemental imaging and biopsies before and after notification laws in 12 states enacting breast density notification laws from 2009 to 2014 and 12 matched control states. Supplemental imaging/biopsy within 6 months following an index mammogram were evaluated during four time periods related to legislation: (1) 6 months before, (2) 0–6 months after, (3) 6–12 months after, and (4) 12–18 months after.

Participants

Women ages 40–64 years receiving an initial mammogram in a state that passed a breast density notification law or a control state.

Intervention

Mandatory breast density notification following an index mammogram.

Main Measures

Use of breast biopsies and supplemental breast imaging (breast ultrasound, tomosynthesis, magnetic resonance imaging, scintimammography, and thermography), overall and by specific test.

Key Results

Supplemental breast imaging and biopsy increased modestly in states with notification laws and changed minimally in control states. Adjusted rates of supplemental imaging and biopsy within 6 months of mammography before legislation were 8.5% and 3.1%, respectively. Compared with pre-legislation in intervention and control states, legislation was associated with adjusted difference-in-differences estimates of + 1.3% (p < 0.0001) and + 0.4% (p < 0.0001) for supplemental imaging and biopsies, respectively, in the 6–12 months after the law and difference-in-differences estimates of + 3.3% (p < 0.0001) and + 0.8% (p < 0.0001) for supplemental imaging and biopsies, respectively, 12–18 months after the law.

Conclusions

As breast density notification laws are considered, policymakers and clinicians should expect increases in breast imaging/biopsies. Additional research is needed on these laws’ effects on cost and patient outcomes.

KEY WORDS

breast cancer cancer screening health communication health policy health services research 

Notes

Acknowledgements

We acknowledge and sincerely thank Dr. Kenneth L. Kehl for his guidance and consultation on methodology for determining an incidence cohort for breast cancer from the Truven Marketscan claims databases.

Funding

Dr. Saulsberry’s effort was supported by R25 CA92203 from the National Cancer Institute. Dr. Pace’s effort was supported by an American Cancer Society Cancer Control Career Development Award for Primary Care Physicians and 1K07CA215819-01A1 from the National Cancer Institute. Dr. Keating’s effort was supported by K24CA181510 from the National Cancer Institute.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

References

  1. 1.
    Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst. 2014;106(10):1–6.CrossRefGoogle Scholar
  2. 2.
    Stomper PC, D’Souza DJ, DiNitto PA, Arredondo MA. Analysis of parenchymal density on mammograms in 1353 women 25-79 years old. AJR Am J Roentgenol. 1996;167:1261–5.CrossRefGoogle Scholar
  3. 3.
    Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol. 1976;126:1130–70.CrossRefGoogle Scholar
  4. 4.
    Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer. 1976;37:2486–92.CrossRefGoogle Scholar
  5. 5.
    McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1159–69.CrossRefGoogle Scholar
  6. 6.
    Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227–36.CrossRefGoogle Scholar
  7. 7.
    Connecticut Bill 458, Public Act No. 9—41. An act requiring communication of mammographic breast density information to patients, 2009. https://www.cga.ct.gov/2009/ACT/PA/2009PA-00041-R00SB-00458-PA.htm. Accessed January 23, 2018.
  8. 8.
    Legislation and regulation-notification requred by state. 2019. Accessed at https://densebreastinfo.org/legislation.aspx Accessed January 23, 2018.
  9. 9.
    Lee CI, Bassett LW, Lehman CD. Breast density legislation and opportunities for patient-centered outcomes research. Radiology. 2012;264:632–6.CrossRefGoogle Scholar
  10. 10.
    Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:268–78.CrossRefGoogle Scholar
  11. 11.
    Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasounds and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299(18):2151–63.CrossRefGoogle Scholar
  12. 12.
    Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394–404.CrossRefGoogle Scholar
  13. 13.
    USPSTF. Summary on breast cancer screening guidelines. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening1. Accessed January 23, 2018.
  14. 14.
    Sprague BL, Stout NK, Schechter C, et al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015;162(3):157–66.CrossRefGoogle Scholar
  15. 15.
    Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, Philpotts LE. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41. Radiology. 2012;265(1):59–69.CrossRefGoogle Scholar
  16. 16.
    Weigert J, Steenbergen S. The Connecticut Experiment: the role of ultrasound in the screening of women with dense breasts. Breast J. 2012;18(6):517–22.CrossRefGoogle Scholar
  17. 17.
    Parris T, Wakefield D, Frimmer H. Real world performance of screening breast ultrasound following enactment of Connecticut Bill 458. Breast J. 2013;19(1):64–70.CrossRefGoogle Scholar
  18. 18.
    Mason C, Yokubaitis K, Howard E, Shah Z, Wang J. Impact of Henda’s law on the utilization of screening breast magnetic resonance imaging. Proc (Bayl Univ Med Cent). 2015;28(1):7–9.CrossRefGoogle Scholar
  19. 19.
    Horny M, Cohen AB, Duszak R Jr, Christiansen CL, Shwartz M, Burgess JF Jr. Dense breast notification laws: impact on downstream imaging after screening mammography. Med Care Res Rev. 2018; 00(0): 1–19.Google Scholar
  20. 20.
    Truven Health Analytics. IBM Watson Health. MarketScan Databases. http://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases. Accessed January 23, 2018.
  21. 21.
    Centers for Disease Control and Prevention. Behavioral risk factor surveillance system. 2014 survey data and documentation. https://www.cdc.gov/brfss/annual_data/annual_2014.html. Accessed January 23, 2018.
  22. 22.
    National Committee for Quality Assurance: HEDIS® 2014: Healthcare effectiveness data and information set. http://www.ncqa.org/Portals/0/HEDISQM/ HEDIS2014/List_of_HEDIS_2014_Measures.pdf. Accessed January 23, 2018.
  23. 23.
    Wharam JF, Landon B, Zhang F, Xu X, Sourmerai S, Ross-Degnan D. Mammography rates 3 years after the 2009 US Preventive Services Task Force guidelines changes. J Clin Oncol. 2015;33(9):1067–74.CrossRefGoogle Scholar
  24. 24.
    Cole EB, Pisano ED. Tomosynthesis for breast cancer screening. Clin Imaging. 2016;40(2):283–7.CrossRefGoogle Scholar
  25. 25.
    Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499–2507.CrossRefGoogle Scholar
  26. 26.
    Rafferty EA, Durand MA, Conant EF, et al. Breast cancer screening using tomosynthesis and digital mammography in dense and nondense breasts. JAMA. 2016;315(16):1784–1786.CrossRefGoogle Scholar
  27. 27.
    Corsetti V, Houssami N, Ghirardi M, et al. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year followup. Eur J Cancer. 2011;47:1021–1026.CrossRefGoogle Scholar
  28. 28.
    Kelly KM, Dean J, Comulada WS, Lee SJ. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol. 2010;20(3):734–42.CrossRefGoogle Scholar
  29. 29.
    Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013;14(7):583–589.CrossRefGoogle Scholar
  30. 30.
    Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013;267(1):47–56.CrossRefGoogle Scholar
  31. 31.
    Berg WA. Tailored supplemental screening for breast cancer: what now and what next? AJR. 2009;192(2):390–399.CrossRefGoogle Scholar
  32. 32.
    Rhodes DJ, Hruska CB, Conners AL, et al. Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. AJR Am J Roentgenol. 2015;204(2):241–251.CrossRefGoogle Scholar
  33. 33.
    Moskowitz M, Milbrath J, Gartside P, Zermeno A, Mandel D. Lack of efficacy of thermography as a screening tool for minimal and stage I breast cancer. N Engl J Med. 1976; 295:249–252.CrossRefGoogle Scholar
  34. 34.
    Feig SA, Shaber GS, Schwartz GF, et al. Thermography, mammography, and clinical examination in breast cancer screening. Review of 16,000 studies. Radiology. 1977;122(1):123-127.CrossRefGoogle Scholar
  35. 35.
    Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2015;155(1):165–73.CrossRefGoogle Scholar
  36. 36.
    Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39(6 Pt 1):1733–49.CrossRefGoogle Scholar
  37. 37.
    Agresti A. Categorical Data Analysis. 3rd edition. Hoboken, New Jersey: John Wiley & Sons; 2013.Google Scholar
  38. 38.
    Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA. 2014;312(22):2401–2402.CrossRefGoogle Scholar
  39. 39.
    Karaca-Mandic P, Norton EC, Dowd B. Interaction terms in nonlinear models. Health Serv Res. 2012;47(1):255–274.CrossRefGoogle Scholar
  40. 40.
    U.S. Food and Drug Administration. Mammography Quality Standards Act and Program (MQSA) National Statistics. https://www.fda.gov/Radiation-EmittingProducts/MammographyQualityStandardsActandProgram/FacilityScorecard/ucm113858.htm. Accessed January 23, 2018.
  41. 41.
    Berg WA. Current status of supplemental screening in dense breasts. J Clin Oncol. 2016;34(16):1840–1843.CrossRefGoogle Scholar
  42. 42.
    Richman I, Asch SM, Bendavid E, Bhattacharya J, Owens DK. Breast density notification legislation and breast cancer stage at diagnosis: early evidence form the SEER Registry. J Gen Intern Med. 2017;32(6): 603–609.CrossRefGoogle Scholar
  43. 43.
    Food and Drug Administration. 21 CFR Part 900 Mammography Quality Standards Act; Federal Register. March 28, 2019; Volume 84 (60): 11669-11686. https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UCM634476.pdf. Accessed April 29, 2019
  44. 44.
    Senate Report 115-259. Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bill, 2019. https://www.congress.gov/congressional-report/115th-congress/senate-report/259/1?q=%7B%22search%22%3A%5B%22farm%22%5D%7D. Accessed April 29, 2019.

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  • Loren Saulsberry
    • 1
  • Lydia E. Pace
    • 2
    • 4
  • Nancy L. Keating
    • 3
    • 4
    Email author
  1. 1.Department of Public Health Sciences, The University of ChicagoChicagoUSA
  2. 2.Division of Women’s HealthBrigham and Women’s HospitalBostonUSA
  3. 3.Department of Health Care Policy Harvard Medical SchoolBostonUSA
  4. 4.Division of General Internal MedicineBrigham and Women’s HospitalBostonUSA

Personalised recommendations